<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163643</url>
  </required_header>
  <id_info>
    <org_study_id>637</org_study_id>
    <nct_id>NCT01163643</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome</brief_title>
  <official_title>A Randomized, Double-Masked, Parallel-Group, Vehicle Controlled, Multicenter, Exploratory Study Assessing the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to identify the concentration and daily dosing frequency of
      BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Adverse Events(AE's)</measure>
    <time_frame>Visit 7; 12 weeks</time_frame>
    <description>Treatment emergent ocular AE's</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal Staining Score</measure>
    <time_frame>Each visit and change from baseline to each visit, over 12 weeks</time_frame>
    <description>Total corneal staining score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst visual analog scale(VAS) dry eye symptom</measure>
    <time_frame>Each visit and change from baseline to each visit, over 12 weeks</time_frame>
    <description>Worst VAS dry eye symptom</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>0.3% BOL-303242-X ophthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3% BOL-303242-X ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% BOL-303242-X ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% BOL-303242-X ophthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% BOL-303242-X ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension in the morning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension PM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% BOL-303242-X ophthalmic suspension</intervention_name>
    <description>0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
    <arm_group_label>0.3% BOL-303242-X ophthalmic suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% BOL-303242-X ophthalmic suspension</intervention_name>
    <description>2% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: Vehicle</intervention_name>
    <description>Placebo Comparator: Vehicle BID for 12 weeks.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% BOL-303242-X ophthalmic suspension</intervention_name>
    <description>1% BOL-303242-X ophthalmic suspension BID for 12 weeks.</description>
    <arm_group_label>1% BOL-303242-X ophthalmic suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% BOL-303242-X ophthalmic suspension AM</intervention_name>
    <description>2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.</description>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension in the morning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% BOL-303242-X ophthalmic suspension PM</intervention_name>
    <description>Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.</description>
    <arm_group_label>2% BOL-303242-X ophthalmic suspension PM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have a diagnosis of dry eye disease.

          -  Intraocular pressure (IOP) â‰¤28 mmHg with no IOP lowering medications.

          -  Subjects who are willing and able to refrain from using contact lenses during the
             study.

        Exclusion Criteria:

          -  Subjects with known hypersensitivity or contraindication to any component of the study
             medication.

          -  Subjects who are expected to require concurrent treatment with ophthalmic medications
             (prescription or over the counter).

          -  Subjects who are expected to require treatment with corticosteroids during the study.

          -  Subjects who have used topical or systemic isotretinoin, cyclosporine, or retinoid
             therapies within 30 days prior to the screening visit.

          -  Subjects who have undergone any type of ocular surgery within three months prior to
             screening.

          -  Lacrimal punctal occlusion (plugs or cautery) within 2 months of Screening Visit.

          -  Subjects with a history or presence of chronic generalized systemic or ocular disease
             that the Investigator feels might increase the risk to the subject or confound the
             result of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuyen Ong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <disposition_first_submitted>March 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 3, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 7, 2012</disposition_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

